Triomics
Latest round
- Series B
Last raised
- May 2026
Total raised
- $37M
Investors
- 7
About Triomics
Based in the US, Triomics, Inc.Founded in 2021 and headquartered in New York, US, Triomics, Inc. focuses on developing AI technology for healthcare. The founding team includes Hrituraj Singh, Roman Bieliaiev, and Sarim Khan, contributing to the company's innovative approach in health technology.Triomics specializes in advanced AI-driven solutions that transform unstructured electronic health records (EHR) into structured, actionable datasets tailored for oncology workflows. The company's core product utilizes AI agents that analyze comprehensive patient records, including notes, reports, and faxes, to produce a structured view that enables healthcare teams to make informed decisions throughout a patient's care journey. Triomics' technology enhances clinical trial matching, enabling coordinators to efficiently identify candidates for trials, significantly reducing time spent on patient chart reviews. The platform serves a diverse client base, including NCI-designated cancer centers and community oncology practices across the United States, particularly in Connecticut and New York.Triomics generates revenue through a subscription-based model, providing its AI platform to healthcare institutions and cancer centers that seek to improve clinical trial matching and patient management.30. The company engages in direct partnerships with oncology practices and hospitals, offering tailored solutions that enhance their existing workflows. Transactions typically involve annual or multi-year agreements, where clients pay for access to the Triomics platform, which includes features such as real-time trial matching and comprehensive patient data abstraction.In May 2026, Triomics, Inc. The company plans to grow its AI/engineering and forward-deployed teams while advancing its AI agents for clinical care and research. Upcoming product developments are focused on enhancing AI capabilities for better integration within oncology practices. The funds will support expansion efforts, including targeting new geographic regions and markets, with specific strategies to reach a broader client base by 2027.
Who invested in Triomics
7 investors across 2 rounds
See all investors in Triomics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Triomics
Who invested in Triomics?
Triomics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Triomics raised?
Triomics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Triomics last raise money?
Triomics's most recent round on record is a Series B, in May 2026.
What does Triomics do?
Based in the US, Triomics, Inc.
Where is Triomics headquartered?
Triomics is headquartered in New York, US.
Which VCs invest in companies like Triomics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back healthcare it companies at Triomics's stage. Their profiles are linked below.
VCs backing healthcare it startups at Series B
Raising like Triomics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.